Postmenopausal tibolone therapy: Biologic principles and applied clinical practice

MedGenMed Medscape General Medicine

Volumn 9, Issue 1, 2007, Pages

  Notelovitz, Morris ^a,b  

^a Adult Women's Health and Medicine   (United States)

^b Adult Women's Health and Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3ALPHA HYDROXYTIBOLONE; 3BETA HYDROXYTIBOLONE; ALENDRONIC ACID; ANDROGEN; CALCIUM; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; DELTA 4 TIBOLONE; DRUG METABOLITE; ESTRADIOL; ESTRADIOL PLUS NORETHISTERONE ACETATE; ESTROGEN; HORMONE RECEPTOR; NORETYNODREL; PLACEBO; PROGESTERONE; PROGESTERONE DERIVATIVE; RISEDRONIC ACID; SEX HORMONE; TIBOLONE; UNCLASSIFIED DRUG; PREGNANE DERIVATIVE;

ANDROGEN SYNTHESIS; ARTICLE; BREAST; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG SPECIFICITY; ENDOMETRIUM; ESTROGEN ACTIVITY; ESTROGEN SYNTHESIS; HORMONE RESPONSE; HUMAN; MENOPAUSAL SYNDROME; MONOTHERAPY; OPTIMAL DRUG DOSE; OSTEOPOROSIS; POSTMENOPAUSE; PROTEIN LOCALIZATION; PROTEIN POLYMORPHISM; DRUG POTENTIATION; FEMALE; METABOLISM; NEOPLASM; PHYSIOLOGY; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; SIGNAL TRANSDUCTION;

CARDIOVASCULAR DISEASES; ESTROGENS; FEMALE; HUMANS; NEOPLASMS; NORPREGNENES; OSTEOPOROSIS, POSTMENOPAUSAL; POSTMENOPAUSE; SIGNAL TRANSDUCTION;

EID: 33846333540     PISSN: 15310132     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (100)

1. Writing group for the Women's Health Initiative investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333. Abstract
2. Notelovitz M. The clinical practice impact of the Women's Health Initiative: political vs biological correctness. Maturitas. 2003;44:3-9. Abstract
3. Riggs BK, Hartmann LC. Selective estrogen receptor modulators - mechanism of action and application to clinical practice. N Engl J Med. 2003;345:618-629.
4. Chetrite GS, Pasqualini JR. The selective estrogen enzyme modulator (SEEM) in breast cancer. J Steroid Biochem Mol Biol. 2001;76:95-104. Abstract
5. Kloosterboer HJ. Tibolone: a steroid with a tissue-specific mode of action. J Steroid Biochem Mol Biol. 2001;70:231-238.
6. Burger HG. Androgen production in women. Fertil Steril. 2002;77(suppl 4):S3-5. Abstract
7. Gruber CJ, Tschugguel W, Schneeburger C, Huber JC. Production and actions of estrogens. N Engl J Med. 2002;346:340-352. Abstract
8. Simpson ER. Aromatization of androgens in women: current concepts and findings. Fertil Steril. 2002;77(suppl 4)S6-10.
9. Zhu BT, Conney AH. Functional role of estrogen metabolism in target cells: review and perspectives. Carcinogenesis. 1998;19:1-27. Abstract
10. Clemmons M, Goss P. Estrogens and the risk of breast cancer. N Engl J Med. 2001;344:276-285. Abstract
11. Nilsson S, Makela S, Treuter E, et al. Mechanisms of estrogen action. Physiol Rev. 2001;81:1535-1565. Abstract
12. Longcope C. Androgens, estrogens and mammary epithelial proliferation. Menopause. 2003;10:274-275. Abstract
13. Vegeto E, Shabnaz M, Wen D, et al. Human progesterone A form is a cell and promotor specific repressor of human progesterone beta function. Mol Endocrinol. 1993;7:1244-1255. Abstract
14. Stanczyk F. Estrogens used for replacement therapy in postmenopausal women. Gynecol Endocrinol. 2001;15(suppl 4)17-25.
15. Notelovitz M. Clinical opinion: The biologic and pharmacologic principles of estrogen therapy for symptomatic menopause. MedGenMed. 2006;8(1):85.
16. O'Brien SN, Anandjiwala J, Price TM. Differences in estrogen content of breast adipose tissue in women by menopausal status and hormone use. Obstet Gynecol. 1997;90:244-248. Abstract
17. Kloosterboer HJ. Tibolone: a steroid with a tissue-specific mode of action. J Steroid Biochem Mol Biol. 2001;76:231-238. Abstract
18. Timmer LJ, Houwing NS. Dose proportionality of three different doses of tibolone. Pharmacotherapy. 2002;22:106-112.
19. Falany JL, Masrina N, Falany CN. Sulfation of tibolone and tibolone metabolites by expressed human cytosolic sulfotransferases. J Steroid Biochem Mol Biol. 2004;88:383-391. Abstract
20. Hofling M, Carlstrom K, Svane G, et al. Different effects of tibolone and continuous combined estrogen plus progestogen hormone therapy on sex hormone binding globulin and free testosterone levels - an association with mammographic density. Gynecol Endocrinol. 2005;20:110-115. Abstract
21. Doren M, Rubig A, Coelingh Bennink HJ, Holzgreve W. Differential effects on the androgen status of postmenopausal women treated with tibolone and continuous combined estradiol and norethindrone acetate replacement therapy. Fertil Steril. 2001;75:554-559. Abstract
22. Osterlund MK, Hurd YL. Estrogen receptors in the human forebrain and the relation to neuropsychiatric disorders. Prog Neurobiol. 2001;64:251-267. Abstract
23. Fernandez-Guasti A, Kruijver, Fodor M, Swaab DF. Sex differences in the distribution of androgen receptors in the human hypothalamus. J Comp Neurol. 2000;425:422-435. Abstract
24. Hobbs CJ, Jones RE, Plymate SR. The effect of sex hormone binding globulin (SHBG) on testosterone transport into the cerebrospinal fluid. J Steroid Biochem Mol Biol. 1992;42:629-635. Abstract
25. Stearns V, Ullmer L, Lopez JF, et al. Hot flushes. Lancet. 2002;360:1851-1861. Abstract
26. Freeman RR, Krell W. Reduced thermoregulatory null zone in postmenopausal women with hot flushes. Am J Obstet Gynecol. 1999;181:66-70. Abstract
27. Nelson HD. Commonly used types of postmenopausal estrogen for treatment of hot flushes. JAMA. 2004;291:1610-1620. Abstract
28. Landgren MB, Helmond FA, Engelen S. Tibolone relieves climacteric symptoms in highly symptomatic women with at least seven hot flushes and sweats per day. Maturitas. 2005;50:222-230 Abstract
29. Winkler UH, Alskemper R, Kwee B, et al. Effects of tibolone and continuous combined hormone replacement therapy on parameters in the clotting cascade: a multicenter, double-blind, randomized study. Fertil Steril. 2000;74:10-19. Abstract
30. Huber J, Palacios S, Berglund L, et al. Effects of tibolone and continuous combined hormone replacement therapy on bleeding rates, quality of life and tolerability in postmenopausal women. Br J Obstet Gynaecol. 2002;109:886-893.
31. Davis SR. The effects of tibolone on mood and libido. Menopause. 2002;9:162-170. Abstract
32. Simon JA. Estrogen replacement therapy: effects on the endogenous androgen milieu. Fertil Steril. 2002(suppl 4):S77-S88.
33. Genazzani AR, Petraglia F, Facchinetti F. Effects of ORG OD14 on pituitary and peripheral beta-endorphin in castrated rats and postmenopausal women. Maturitas. 1987;Suppl 1:35-48. Abstract
34. Albertazzi P, Natale V, Barbolini C, et al. The effect of tibolone versus continuous combined norethisterone acetate and oestradiol on memory, libido and mood of postmenopausal women: a pilot study. Maturitas. 2000;36:223-229. Abstract
35. Davis SR, McCloud PI, Strauss BJG, Burger HG. Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. Maturitas. 1995;21:227-236. Abstract
36. Nathorst-Boos J, Hammar M. Effect on sexual life - a comparison between tibolone and a continuous estradiol-norethisterone acetate regimen. Maturitas. 1997;26:15-26. Abstract
37. Castelo-Branco C, Vicente JJ, Figueras F, et al. Comparative effects of estrogens plus androgens and tibolone on bone, lipid pattern and sexuality in postmenopausal women. Maturitas. 2000;34:161-168. Abstract
38. Laan E, van Lunsen W, Everaerd W. The effects of tibolone on vaginal blood flow, sexual desire and arousability in postmenopausal women. Climacteric. 2001;4:28-41. Abstract
39. Morris E, Wilson P, Robinson J, Rymer J. Long term effects of tibolone on the genital tract in postmenopausal women. Br J Obstet Gynaecol. 1999;106:954-959. Abstract
40. Matsuzaki S, Fukaya T, Suzuki T, et al. Oestrogen receptor á and beta mRNA expression in human endometrium throughout the menstrual cycle. Mol Hum Reprod. 1999;5:559-564. Abstract
41. Petterson K, Delaunay F, Gustafson JA. Estrogen receptor beta acts as a dominant regulator of estrogenic signaling. Oncogene. 2000;19:4970-4978. Abstract
42. Wang H, Critchley HO, Kelly RW, et al. Progesterone receptor subtype B is differentially regulated in human endometrial stroma. Mol Hum Reprod. 1998;4:407-412. Abstract
43. Rubin GL, Harrold AJ, Mills JA, et al. Regulation of sulphotransferase expression in endometrium during the menstrual cycle, by oral contraceptives and during early pregnancy. Mol Hum Reprod. 1999;5:995-1002. Abstract
44. Hammar M, Christau S, Nathorst-Boos J, et al. A double-blind randomized trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms. Br J Obstet Gynaecol. 1998;105:904-911. Abstract
45. Archer DF, MacIntyre-Seltman K, Wilborn WW, et al. Endometrial morphology in asymptomatic postmenopausal women. Am J Obstet Gynecol. 1991;165:317-320. Abstract
46. Pickar JH, Archer DF. Is bleeding a predictor of endometrial hyperplasia in postmenopausal women receiving hormone replacement therapy. Am J Obstet Gynecol. 1997; 177:1178-1183.
47. Langer RD, Landgren BM, Rymer J, et al. Effects of tibolone and continuous combined conjugated equine estrogen/medroxyprogesterone acetate on the endometrium and vaginal bleeding. Results of the OPAL Study. Am J Obstet Gynecol. 2006; in press.
48. Rose PG. Endometrial carcinoma. N Engl J Med. 1996;335:640-649. Abstract
49. de Vries CS, Bromley SE, Thomas H, Farmer RDT. Tibolone and endometrial cancer: a cohort and nested case-control study in the UK. Drug Saf. 2005;28:241-249. Abstract
50. Velthuis-te Wierk EJM, Hendricks PT, Boerstoel-Streefland M. Clinical background of women prescribed tibolone or combined estrogen and progestogen therapies: a UK Mediplus study. Climacteric. 2004;7:197-209. Abstract
51. Clemmons M, Goss P. Estrogen and the risk of breast cancer. N Engl J Med. 2002;344:276-285.
52. Gingrass S, Cote S, Simard J. Multiple signal transduction pathways mediate interleukin-4-induced 3beta-hydroxysteroid dehydrogenase/ Ä5-Ä4 isomerase in normal and tumoral target tissues. J Steroid Biochem Mol Biol. 2001;76:213-225. Abstract
53. Pasqualini HJR, Chetrite G, Nguyen BL, et al. Estrone-sulfate-sulfatase and 17-beta hydroxysteroid dehydrogenase activities: a hypothesis for their role in the evolution of human breast cancer from hormone dependence to hormone independence. J.Steroid Biochem Mol Biol. 1995;53:407-412.
54. Van de Ven J, Donker G, Sprong M, et al. Effect of tibolone (ORG OD14) and its metabolites on aromatase and estrone sulfatase activity in human breast adipose stromal cells and in MCF-7 and T47D breast cancer cells. J Steroid Biochem Mol Biol. 2002;81:237-247. Abstract
55. Gompel A, Siromachkoya M, Lombet A, et al. Tibolone actions on normal and breast cancer cells. Eur J Cancer. 2000;36 (suppl):S76-S77.
56. Conner P, Christow A, Kersemaekers W, et al. A comparative study of breast cell proliferation during hormone replacement therapy: effects of tibolone and continuous combined estrogen-progestogen treatment. Climacteric. 2004;7:50-58. Abstract
57. Chetrite GS, Kloosterboer HJ, Phillipe JC, et al. Effects of ORG OD14 (livial) and its metabolites in human estrogen sulfotransferase activity in the hormone dependent MCF-7 and T-47D, and the hormone independent MDA-MB-231 breast cancer cell lines. Anticancer Res. 1999;19:269-275. Abstract
58. de Gooyer ME, Kleyn GT, Smits KC, et al. Tibolone: a compound with tissue specific inhibitory effects on sulfatase. Mol Cell Endocrinol. 2001;183:55-62. Abstract
59. Lundstrom E, Christow A, Kersemaekers W, et al. Effects of tibolone and continuous combined hormone replacement therapy on mammographic breast density. Am J Obstet Gynecol. 2002; 186:717-722. Abstract
60. Hofling M, Carlstrom K, Svane G, et al. Different effects of tibolone and continuous combined estrogen plus progestogen hormone therapy on sex hormone binding globulin and free testosterone levels - an association with marnmographic density. Gynaecol Endocrinol. 2005;20:110-115.
61. Speroff L. The meaning of mammographic breast density in users of postmenopausal hormone therapy. Maturitas. 2002;41:171-175. Abstract
62. Beral V, Million Women Study collaborators. Breast cancer and hormone replacement therapy in the Million Women Study. Lancet. 2003;362:419-427. Abstract
63. Speroff L. The Million Women Study and breast cancer. Editorial. Maturitas. 2003;46:1-6. Abstract
64. Allen DS, De Vries SS, Farmer RDT. Pharmaceutical content and regimen of hormone replacement therapy and risk of breast cancer. Pharmacoepidemiology and Drug Safety. 2002; 11 (suppl 1):296.
65. Stahlberg C, Pedersen AJ, Lynge E, et al. Increased risk of breast cancer following different regimens of hormone replacement therapy frequently used in Europe. Int J Cancer. 2004;109:721-727. Abstract
66. Jamin C, Bourg F, Legeai J, Senoussi S. Is the clinical profile of women treated with tibolone similar to that of women receiving a classical estrogen-progestogen therapy? Data from a nationwide survey in France. Gynecol Obstet Fertil. 2006;34:224-232. Abstract
67. Notelovitz M. Androgen effects on bone and muscle. Fertil Steril. 2002;77:(suppl 4):S34-41.
68. Bord S, Horner A, Beavan S, Compston J. Estrogen receptors á and beta are differential expressed in developing human bone. J Clin Endocrinol Metab. 2001;86:2309-2314. Abstract
69. Abu EO, Horner A, Kurec V, et al. The localization of androgen receptors in human bone. J Clin Endocrinol Metab. 1997;82:3493-3497. Abstract
70. MacNamara P, Loughrey HC. Progesterone receptor A and B isoform expression in human osteoblasts. Calcif Tissue. 1998;63:39-46.
71. Sunyer T, Lewis J, Collin-Osdoby P, Osdoby P. Estrogen's bone protective effect may involve differential IL-1 receptor regulation in human osteoblast-like cells. J Clin Invest. 1999;103:1409-1418. Abstract
72. Verborgt O, Gibson GJ, Schaffer MB. Loss of osteocytes integrity with microdamage and bone remodeling after fatigue in vivo. J Bone Miner Res. 2000;15:60-67. Abstract
73. Janssen JMMF, Bland R, Hewison M, et al. Estradiol formation by human osteoblasts via multiple pathways: relation with osteoblast function. J Cell Biol. 1999;75:528-537.
74. Richard DJ, Water KM, Ruesink TJ, et al. Estrogen receptors isoform-specific induction of progesterone receptors in human osteoblasts. J Bone Miner Res. 2002;17:1580-1592.
75. Gallagher JC, Baylink DJ, Freeman R, McClung M. Prevention of bone loss with tibolone in postmenopausal women. Results of two randomized, double-blind placebo-controlled, dose-finding studies. J Clin Endocrinol Metab. 2001;86:4717-4726. Abstract
76. McClung M, Clemmeson B, Daifotus A, et al. Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind randomized controlled trial. Ann Intern Med. 1998;128:253-261. Abstract
77. Delmas PED, Bjarnason JH, Mitlak RH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med. 1997;337:1641-1647. Abstract
78. Mortenson I, Charles P, Bekker PJ, et al. Residronate increases bone mass in early postmenopausal population: two years of treatment plus one year follow-up. J Clin Endocrinol Metab. 1998;83:396-402. Abstract
79. Bjarnason NH, Bjarnason K, Haarbro J, et al. Tibolone: prevention of bone loss in late postmenopausal women. J Clin Endocrinol Metab. 1996;81:2419-2422. Abstract.
80. Studd J, Arnala I, Kicovic PM, et al. A randomized study of tibolone on bone mineral density in osteoporotic postmenopausal women with previous fractures. Obstet Gynecol. 1998;92:574-579. Abstract
81. Rymer J, Robinson J, Fogelman I. Ten years of treatment with tibolone 2.5mg daily: effects of bone loss in postmenopausal women. Climacteric. 2002;5:390-398. Abstract
82. Roux C, Pelissier C, Fechtenbaum J, et al. Randomized, double-masked, 2 year comparison of tibolone with 17beta estradiol and norethindrone acetate in preventing postmenopausal bone loss. Osteoporos Int. 2002;13:241-248. Abstract
83. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med. 1999;340:1801-1811 Abstract
84. Losordo DW, Kearney M, Kim EA, et al. Variable expression of the estrogen receptor in normal and atherosclerotic arteries of premenopausal women. Circulation. 1994;89:1501-1510. Abstract
85. Post WS, Goldschmidt-Clemont PJ, Wilhide CC, et al. Methylation of the estrogen receptor gene in association with aging and atherosclerosis in the cardiovascular system. Cardiovasc Res. 1999;43:985-991. Abstract
86. Cummings SR. LIFT study is discontinued. BMJ. 2006;332:667.
87. Cagnacci A, Mallus E, Tuveri F, et al. Effect of tibolone on glucose and lipid metabolism in postmenopausal women. J Clin Endocrinol Metab. 1997;82:251-253. Abstract
88. Lloyd G, McGing E, Cooper A, et al. A randomized placebo controlled trial of the effects of tibolone on blood pressure and lipids in hypertensive women. J Hum Hypertens. 2000;14:99-104. Abstract
89. Winkler UH, Altkemper R, Kwee B, et al. Effects of tibolone and continuous combined hormone therapy on parameters in the coagulation cascade: a multicenter, double blind, randomized study. Fertil Steril. 2000;74:10-19. Abstract
90. Milner MH, Sinnott MM, Cooke TM et al. A 2-year study of lipid and lipoprotein changes in postmenopausal women with tibolone and estrogen-progestin. Obstet Gynecol. 1996;87:503-599.
91. Bjarnason NH, Bjarnason K, Haarbo J, et al. Tibolone: influence on markers of cardiovascular disease. J Clin Endocrinol Metab. 1997;82:1752-1756. Abstract
92. von Eckardstein A, Crook D, Elbers J, et al. Tibolone lowers high density lipoprotein cholesterol by increasing hepatic lipase activity but does not impair cholesterol efflux. Clin Endocrinol. 2002;58:49-58.
93. Mikkola TS, Anthony MS, Clarkson TB, St Clair RW. Serum cholesterol efflux potential is an independent predictor of coronary artery atherosclerosis. Atherosclerosis. 2003;170:31-38. Abstract
94. Brewer HB. Increasing HDL cholesterol levels. N Engl J Med. 2004;350:1491-1494. Abstract
95. Clarkson TB, Anthony MS, Wagner JD. A comparison of tibolone and conjugated equine estrogen effects on coronary artery atherosclerosis and bone density of postmenopausal monkeys. J Clin Endocrinol Metab. 2001;86:5396-5404 Abstract
96. von Eckardstein, Schmiddem K, Hovels A, et al. Lowering HDL cholesterol in postmenopausal women by tibolone is not associated with changes in cholesterol efflux capacity or paraoxonase activity. Atherosclerosis. 2001;159:433-439. Abstract
97. Morris EP, Denton ER, Robinson J, et al. High resolution ultrasound assessment of the carotid artery: its relevance in postmenopausal women and the effects of tibolone on carotid artery ultrastructure. Climacteric. 1999;2:13-20. Abstract
98. Visvanathan K, Gallicchio L, Schilling C, et al. Cytochrome gene polymorphisms, serum estrogens and hot flushes in midlife women. Obstet Gynecol. 2005;106:1372-1381. Abstract
99. Notelovitz M. Pharmacology during the menopausal transition. In: Schneider HPG, Naftolin F, eds. Climacteric Medicine Where Do We Go? Abingdon, UK: Taylor & Francis; 2005; p 110-119
100. Lenfant C. Clinical research to clinical practice - lost in translation? N Engl J Med. 2003;349:868-874.